Posted by Michael Wonder on 06 Dec 2024
US FDA approves StemCyte biologics license application for Regenecyte cord blood cell therapy product
22 November 2024 - StemCyte announced today that the US FDA has approved the Biologics License Application for its HPC, cord blood product Regenecyte, a vital cord blood stem cell therapy for transplantation in patients with blood and immune system disorders.
With this approval, StemCyte became the 15th company to receive BLA approval in 2024 and the first commercial US based biotech company to secure a biologics license for cord blood stem cell therapy.
